Pfizer

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

June 4, 2018

The Future of BioManufacturing: In Silico Modelling

October 16, 2017
Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence

Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery

September 26, 2017

The Future of BioManufacturing: Cell Line Engineering

August 25, 2017

The Future of BioManufacturing: The Promise of Perfusion

June 14, 2017

The Future of BioManufacturing: Modular Factories & End-to-End Solutions

August 23, 2016
Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation […]
February 21, 2016
Evolution Infographic: The Rise & Diversification of Biologics

Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that […]
Contact Us